CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Geron Reiterates 2026 RYTELO Net Product Revenue Guidance of $220 Million-$240 Million

By Public Technologies
  • Geron discontinued its IMpactMF trial of imetelstat in relapsed or refractory myelofibrosis in October 2026.
  • Expected 2026 RYTELO net product revenue remains $220 million-$240 million, with total operating expenses projected at $230 million-$240 million.
  • RYTELO net product revenue rose 17% year over year in the second quarter; demand volume increased 5% sequentially.
  • Plans call for communicating RYTELO's European commercial strategy for lower-risk myelodysplastic syndromes by the end of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk